Literature DB >> 19816673

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

N Tolonen1, C Forsblom, L Thorn, J Wadén, M Rosengård-Bärlund, M Saraheimo, M Feodoroff, V-P Mäkinen, D Gordin, M-R Taskinen, P-H Groop.   

Abstract

AIMS/HYPOTHESIS: We studied the impact of baseline lipid variables on the progression of renal disease in a large nationwide prospective cohort of patients with type 1 diabetes.
METHODS: A total of 2,304 adult patients with type 1 diabetes and available lipid profiles participating in the Finnish Diabetic Nephropathy Study (FinnDiane) were evaluated. Data on progression of renal disease were verified from medical files and patients were followed for 5.4 +/- 2.0 (mean +/- SD) years.
RESULTS: High triacylglycerol, apolipoprotein (Apo) B, ApoA-II and HDL(3)-cholesterol concentrations predicted incident microalbuminuria. Progression to macroalbuminuria was predicted by high triacylglycerol and ApoB. When AER was entered into the model, triacylglycerol was no longer an independent predictor, but when patients with normal AER and microalbuminuria at baseline were pooled, triacylglycerol, HbA(1c), male sex and AER were all independent predictors of renal disease. High total cholesterol, LDL-cholesterol, non-HDL-cholesterol and triacylglycerol as well as low HDL-cholesterol, HDL(2)-cholesterol, ApoA-I and ApoA-II concentrations were predictive of progression to end-stage renal disease. However, when estimated GFR was entered into the model, only total cholesterol remained an independent predictor of progression. CONCLUSIONS/
INTERPRETATION: Lipid abnormalities, particularly high triacylglycerol concentrations, increase the risk of progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816673     DOI: 10.1007/s00125-009-1541-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.

Authors:  Jarir Atthobari; Auke H Brantsma; Ron T Gansevoort; Sipke T Visser; Folkert W Asselbergs; Wiek H van Gilst; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Nephrol Dial Transplant       Date:  2006-05-23       Impact factor: 5.992

2.  The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus.

Authors:  S P Laing; A J Swerdlow; S D Slater; J L Botha; A C Burden; N R Waugh; A W Smith; R D Hill; P J Bingley; C C Patterson; Z Qiao; H Keen
Journal:  Diabet Med       Date:  1999-06       Impact factor: 4.359

3.  Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins.

Authors:  G J Hopkins; P J Barter
Journal:  J Lipid Res       Date:  1986-12       Impact factor: 5.922

4.  Prognosis in diabetic nephropathy.

Authors:  H H Parving; E Hommel
Journal:  BMJ       Date:  1989-07-22

5.  Serum lipids and the progression of nephropathy in type 1 diabetes.

Authors:  Merlin C Thomas; Milla Rosengård-Bärlund; Vashti Mills; Mats Rönnback; Stephen Thomas; Carol Forsblom; Mark E Cooper; Marja-Riitta Taskinen; Giancarlo Viberti; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

6.  Multiple lipoprotein abnormalities in type I diabetic patients with renal disease.

Authors:  P H Groop; T Elliott; A Ekstrand; A Franssila-Kallunki; R Friedman; G C Viberti; M R Taskinen
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

7.  Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

Authors:  Trevor J Orchard; Yue-Fang Chang; Robert E Ferrell; Nancy Petro; Demetrius E Ellis
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

8.  Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland.

Authors:  J Tuomilehto; K Borch-Johnsen; A Molarius; T Forsén; D Rastenyte; C Sarti; A Reunanen
Journal:  Diabetologia       Date:  1998-07       Impact factor: 10.122

9.  Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

10.  Smoking is associated with progression of diabetic nephropathy.

Authors:  P T Sawicki; U Didjurgeit; I Mühlhauser; R Bender; L Heinemann; M Berger
Journal:  Diabetes Care       Date:  1994-02       Impact factor: 19.112

View more
  26 in total

1.  Predictors of incident albuminuria in the Framingham Offspring cohort.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Ashish Upadhyay; James B Meigs; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2010-11       Impact factor: 8.860

Review 2.  PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

Authors:  Anne Hiukka; Marianna Maranghi; Niina Matikainen; Marja-Riitta Taskinen
Journal:  Nat Rev Endocrinol       Date:  2010-06-22       Impact factor: 43.330

3.  Sex differences in the development of kidney disease in individuals with type 1 diabetes mellitus: a contemporary analysis.

Authors:  Tina Costacou; Linda Fried; Demetrius Ellis; Trevor J Orchard
Journal:  Am J Kidney Dis       Date:  2011-08-15       Impact factor: 8.860

Review 4.  Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Authors:  Stephen J Cleland
Journal:  Nat Rev Endocrinol       Date:  2012-04-10       Impact factor: 43.330

5.  Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?

Authors:  M C Thomas; J L Moran; V Harjutsalo; L Thorn; J Wadén; M Saraheimo; N Tolonen; J Leiviskä; A Jula; C Forsblom; P H Groop
Journal:  Diabetologia       Date:  2012-02-10       Impact factor: 10.122

6.  Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes.

Authors:  Raija Lithovius; Iiro Toppila; Valma Harjutsalo; Carol Forsblom; Per-Henrik Groop; Ville-Petteri Mäkinen
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

7.  Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.

Authors:  Anne Julie Overgaard; Tine E Thingholm; Martin R Larsen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Clin Proteomics       Date:  2010-09-10       Impact factor: 3.988

8.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

Review 9.  Diabetic nephropathy: diagnosis and treatment.

Authors:  Daniel Fineberg; Karin A M Jandeleit-Dahm; Mark E Cooper
Journal:  Nat Rev Endocrinol       Date:  2013-10-08       Impact factor: 43.330

10.  Relationship between dyslipidemia and albuminuria in prediabetic adults: the Korea National Health and Nutrition Examination Survey 2011-2012.

Authors:  Ga Eun Nam; Kyungdo Han; Do Hoon Kim; Yong Gyu Park; Yeo Joon Yoon; Young Eun Kim; Sangsu Lee; Sungho Lee; Yong Kyun Roh
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.